A Exploratory Trial to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Immunogenicity, and Preliminary Efficacy of WTX221 Infusion in Patients With Refractory Gout
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 入组人数
- 7
- 主要终点
- To evaluate the safety and tolerability of multiple doses of WTX221 infusion combined with a single dose of cyclophosphamide in patients with refractory gout.
研究概览
简要总结
This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to investigate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of multiple doses of WTX221 infusion combined with a single dose of the immunosuppressive agent cyclophosphamide (CTX) to induce immune tolerance.
The trial consisted of a Screening Period (14 days), a First Dose Period (30 days), a Second Dose Period (30 days), and a Safety Follow-up Period (150 days) for a total of 224 days.
详细描述
Refractory gout is usually associated with persistently swollen and tender joints, chronic pain, reduced functional status, impaired quality of life, and joint destruction，most of the patients can't tolerate urate-lowering therapy(ULT)or receive adequate dose of ULT treatment recommended to control Serum uric acid (SUA) to target level.
WTX221 is designed to induce antigen-specific immune tolerance. WTX221 is made of urate oxidase(UOX) molecules conjugated on the surface of Red blood cells(RBCs), which can induce antigen-specific immune tolerance to UOX in vivo by making use of it's natural biologic characteristics. WTX221 infusion combined with a single dose CTX to induce immune tolerance.
The trial consisted of a Screening Period (14 days), a First Dose Period (30 days), a Second Dose Period (30 days), and a Safety Follow-up Period (150 days) for a total of 224 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the informed consent form, and be able to complete all trial processes as required by the protocol;
- •Subject is ≥ 18 years of age;
- •Patients with refractory gout: multiple tophi, more than 2 sites;
- •Subjects (males and females) must agree to be free of childbearing potential and willing to use effective contraception with their partner and have no plans to donate sperm or eggs during the trial and for at least 1 year after the infusion.
排除标准
- •Patients with allergic diseases or specific allergic history, or possible allergic to the study drug and any of its components or related preparations;
- •Patients unable to communicate or cooperate with medical staff due to neurological, mental illness or language disorder, which affects patient compliance;
- •Having any past or present medical history that may affect the safety of the trial or the in vivo process of the drug, especially history of cardiovascular, liver, kidney, digestive tract, lung, spleen, nerve, blood, tumor, immune or metabolic disorders that are considered clinically significant by the investigator;
- •Participated in other drug or medical device clinical trials within 3 months before screening;
- •Patients who have received intravenous anti-infective treatment or active infection within 14 days before administration;
- •Patients with history of allogeneic organ, bone marrow transplantation or stem cell transplantation;
- •Patients with laboratory abnormalities that are clinically significant:
- •The investigator believes that it will prevent the subject from following and completing any other circumstances of the study protocol;
研究组 & 干预措施
Treatment group A
WTX221 low dose
干预措施: WTX221 (Drug)
Treatment group B
WTX221middle dose
干预措施: WTX221 (Drug)
Treatment group C
WTX221 high dose
干预措施: WTX221 (Drug)
结局指标
主要结局
To evaluate the safety and tolerability of multiple doses of WTX221 infusion combined with a single dose of cyclophosphamide in patients with refractory gout.
时间窗: from the first WTX221 infusion to 210 days
Adverse Events and Serious Adverse Events
次要结局
- To evaluate the pharmacokinetic (PK) profile of multiple doses of WTX221 infusion combined with a single dose of cyclophosphamide in patients with refractory gout;(from the first WTX221 infusion to 210 days)
- To evaluate immunogenicity (ADA) levels of multiple doses of WTX221 infusion combined with a single dose of cyclophosphamide in patients with refractory gout(from the first WTX221 infusion to 210days)
- To evaluate the pharmacodynamic (PD) profile of multiple doses of WTX221 infusion combined with a single dose of cyclophosphamide in patients with refractory gout(from the first WTX221 infusion to 210 days)
- To evaluate the preliminary efficacy of multiple doses of WTX221 infusion combined with a single dose of cyclophosphamide in patients with refractory gout(from the first WTX221 infusion to 60days Number of gout flares in subjects (within 60 days);)